Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22241408 | 1.00 | ROCK2 (0.49) | ROCK2PKMCMA1POLBLMNA | |
| SCHEMBL19759551 | 0.92 | CMA1 (0.50) | ROCK2PKMCMA1POLBLMNA | |
| SCHEMBL17920295 | 0.85 | ROCK2 (0.47) | ROCK2PKMCMA1POLBLMNA | |
| SCHEMBL17912954 | 0.84 | ROCK2 (0.60) | ROCK2 | |
| SCHEMBL17920304 | 0.84 | ROCK2 (0.60) | ROCK2 | |
| SCHEMBL17912985 | 0.84 | PKM (0.42) | ROCK2PKMCMA1POLBLMNA | |
| SCHEMBL17912983 | 0.84 | PKM (0.42) | ROCK2PKMCMA1POLBLMNA | |
| SCHEMBL17912991 | 0.83 | PKM (0.48) | ROCK2PKMCMA1POLBLMNA | |
| SCHEMBL19759559 | 0.82 | ROCK2 (0.47) | ROCK2PKMALOX15 | |
| SCHEMBL17912952 | 0.82 | MAPT (0.51) | ROCK2PKMCMA1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406426-B | Cyclic ureas as ROCK inhibitors | 百时美施贵宝公司 | 2020-11-20 | — | — | CN | claimed |
| CN-107406426-B | Cyclic ureas as ROCK inhibitors | 百时美施贵宝公司 | 2020-11-20 | — | — | CN | disclosed |
| EP-3242873-B1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20180000788-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2016112236-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000788-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | MYLK, ROCK1, UACA | ROCK2 4/4885PKM 1485/4885CMA1 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.